The Investor
19 Apr 2026, 12:39
Sanofi announced that its protein-based COVID-19 vaccine Nuvaxovid demonstrated significantly better tolerability than Moderna’s mNEXSPIKE in a head-to-head Phase 4 study. The randomized trial, involving 1,000 adults in the United States, showed lower rates and severity of side effects for Nuvaxovid across all key endpoints.
Results presented at the ESCMID Global Congress indicated that severe systemic reactions were more than 50% less frequent with Nuvaxovid, while moderate-to-severe symptoms were also notably lower compared to the mRNA-based comparator. Participants receiving Nuvaxovid reported less disruption to daily activities and a higher willingness to choose the same vaccine again.
The findings suggest that improved tolerability could help address vaccine hesitancy and support broader uptake of routine COVID-19 vaccination as the disease transitions to an endemic phase.
Results presented at the ESCMID Global Congress indicated that severe systemic reactions were more than 50% less frequent with Nuvaxovid, while moderate-to-severe symptoms were also notably lower compared to the mRNA-based comparator. Participants receiving Nuvaxovid reported less disruption to daily activities and a higher willingness to choose the same vaccine again.
The findings suggest that improved tolerability could help address vaccine hesitancy and support broader uptake of routine COVID-19 vaccination as the disease transitions to an endemic phase.
